ArticleThe EMBO journal2001
Design and development of a catalytic ribonucleoprotein.
Article in The EMBO journal, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 36 citations in OpenAlex.
- Pairwise Engineering of Tandemly Aligned Self-Splicing Group I Introns for Analysis and Control of Their Alternative Splicing.Biomolecules · 2023Article
- Stimulator of Interferon Genes Deficiency in Acute Exacerbation of Idiopathic Pulmonary Fibrosis.Frontiers in immunology · 2017Article
- Coevolution Theory of the Genetic Code at Age Forty: Pathway to Translation and Synthetic Life.Life (Basel, Switzerland) · 2016Article
- Reliable generation of induced pluripotent stem cells from human lymphoblastoid cell lines.Stem cells translational medicine · 2014Article
- RNA plasticity and selectivity applicable to therapeutics and novel biosensor development.Genes to cells : devoted to molecular & cellular mechanisms · 2012Review
- Synthetic translational regulation by an L7Ae-kink-turn RNP switch.Nature chemical biology · 2010Article
- Primitive templated catalysis of a peptide ligation by self-folding RNAs.Nucleic acids research · 2009Article
- Selection of a novel class of RNA-RNA interaction motifs based on the ligase ribozyme with defined modular architecture.Nucleic acids research · 2008Article
- Molecular phylogenetics and functional evolution of major RNA recognition domains of recently cloned and characterized autoimmune RNA-binding particle.Genomics, proteomics & bioinformatics · 2003Article
- Putative intermediary stages for the molecular evolution from a ribozyme to a catalytic RNP.Nucleic acids research · 2003Article
- Selections for constituting new RNA-protein interactions in catalytic RNP.Nucleic acids research · 2003Article
- Group I aptazymes as genetic regulatory switches.BMC biotechnology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ribonucleoproteins (RNPs) consisting of derivatives of a ribozyme and an RNA-binding protein were designed and constructed based upon high-resolution structures of the corresponding prototype molecules, the Tetrahymena group I self-splicing intron RNA and two proteins (bacteriophage lambdaN and HIV Rev proteins) containing RNA-binding motifs. The splicing reaction proceeds efficiently only when the designed RNA associates with the designed protein either in vivo or in vitro. In vivo mutagenic protein selection was effective for improving the capability of the protein. Kinetic analyses indicate that the protein promotes RNA folding to establish an active conformation. The fact that the conversion of a ribozyme to an RNP can be accomplished by simple molecular design supports the RNA world hypothesis and suggests that a natural active RNP might have evolved readily from a ribozyme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.